SecBot SecBot
8-K ·Filed Sep 2, 2026

MNOV

MEDICINOVA INC
BULLISH
Impact 5/10
Horizonimmediate Processed2mo ago SEC0001193125-26-379348
8-K material event: Items 1.02
Actionable Insight ▲ Bullish

The termination removes a dilutive equity line overhang, which is a modest positive for the stock near term. Monitor for any alternative financing arrangements or capital needs, as the company may still require funding for operations or pipeline development.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.43
T+0 close · Sep 2, 2026 · via day close
Latest settled
+17.48%
T+20 · $1.68 · next T+60 in 10d
Vs SPY
+17.57%
α at T+20
Latest observation
−5.62%
T+52 · FF3 residual α
  1. T+0 · Sep 2 $1.43entry
  2. T+1 · 3mo ago +13.29%α +12.24% · $1.62
  3. T+5 · 2mo ago +21.68%α +22.64% · $1.74
  4. T+20 · 7w ago +17.48%α +17.57% · $1.68
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MediciNova terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville, effective September 8, 2026. The SEPA allowed up to $30M in common stock sales but only $0.2M was ever drawn; no outstanding borrowings or fees exist at termination. This removes a potential dilutive overhang, which is a modest positive for existing shareholders.

Key Facts

  • SEPA terminated effective September 8, 2026, by MediciNova's election
  • Original SEPA allowed up to $30.0 million in common stock sales to Yorkville
  • Only 175,000 shares sold for aggregate proceeds of $0.2 million at $1.39–$1.40 per share
  • No outstanding borrowings, advance notices, or shares to be issued at termination
  • No termination fees owed by either party

Financial Impact

Removes potential dilution of up to $30M (approximately 42% of current $71M market cap), though actual dilution was minimal at $0.2M

dilutioncapital structure

Risk Factors

  • Company may need future capital and has lost a flexible financing source
  • Termination could signal difficulty in accessing equity markets on favorable terms

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-379348
Document: 0001193125-26-379348-index-headers.html0001193125-26-379348
Document: 0001193125-26-379348-index.html0001193125-26-379348
Document: 0001193125-26-379348.txt0001193125-26-379348

Track record

6 reports on MNOV

Performance horizon
Filters
  1. Nov 16, 2026today 8-K Bearish 5/10 Entry $1.35 Now $1.34 +0.74% settles Dec 16
  2. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.44 Now $1.34 −6.94% settles Dec 1
  3. Sep 28, 20267w ago Press Release Mixed 5/10 Entry $2.10 to $1.40 Now $1.34 −36.19% ▼ −33.33% −33.30% vs SPY
  4. Sep 24, 20267w ago Press Release Mixed 7/10 Entry $2.65 to $1.41 Now $1.34 −49.43% ▼ −46.79% −46.37% vs SPY
  5. Sep 2, 202610w ago 8-K Bullish 5/10 Viewing Entry $1.43 to $1.68 Now $1.34 −6.29% ▲ +17.48% +17.57% vs SPY
  6. Aug 19, 202612w ago 8-K Neutral 2/10 Entry $1.38 to $3.45 Now $1.34 −2.90% ▲ +150.00% +151.95% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 7h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026